TLANDO

Peak

testosterone undecanoate

NDAORALCAPSULE
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5

Clinical Trials (5)

NCT03851627Phase 4Recruiting

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Started Jan 2022
32 enrolled
Fatty LiverOverweight/ObesityPrediabetes/Type2 Diabetes Mellitus+1 more
NCT04120363Phase 4Completed

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

Started Sep 2019
34 enrolled
Caloric RestrictionExerciseSleep
NCT01346319Phase 1Completed

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Started Apr 2011
0
Hypogonadal Males
NCT00555087Phase 4Unknown

Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

Started May 2007
50 enrolled
Erectile DysfunctionHypogonadotrophic Males
NCT00220298Phase 3Completed

Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism

Started Feb 2003
96 enrolled
Hypogonadism

Loss of Exclusivity

LOE Date
Apr 28, 2041
184 months away
Patent Expiry
Apr 28, 2041

Patent Records (5)

Patent #ExpiryTypeUse Code
11304960
Jan 8, 2029
Product
U-1500
8865695
Jan 8, 2029
U-1500
8778922
Jan 8, 2029
Product
U-1500
11364249
Nov 30, 2030
U-1500
11433083
Nov 30, 2030
U-1500